Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ´Â ±Û·Î¹ú Top tier CDMO ±â¾÷ÀÎ ¿ì½Ã¹ÙÀÌ¿À·ÎÁ÷½ºÀ» ÃÊ´ëÇØ Çõ½Å ±â¼ú ¹× ½Å¾à °³¹ß ³ëÇÏ¿ì¿¡ ´ëÇØ ´Ù¾çÇÑ ÀÇ°ßÀ» ³ª´ ¿¹Á¤ÀÔ´Ï´Ù.
Çùȸ ȸ¿ø»ç ¹× °ü·Ã Á¾»çÀÚ ºÐµéÀÇ ¸¹Àº ½ÅûÀ» ºÎŹ µå¸³´Ï´Ù.
¡à ÀÏÁ¤ : 2023³â 10¿ù 26ÀÏ(¸ñ) 13:00 ~ 14:30
¡à Àå¼Ò : ¿Â¶óÀÎ (Âü°¡ ½Åû Àοø¿¡°Ô ¸µÅ© ¹ß¼Û)
¡à Âü°¡½Åû : Çùȸ ȨÆäÀÌÁö ½Åû
(±³À° ¹× Çà»ç ¡æ Âü°¡½Åû ¡æ ÇØ´ç Çà»ç¸í Ŭ¸¯ ¡æ ÆäÀÌÁö ÇÏ´Ü ½ÅûÇϱâ)
¡à ¹®ÀÇ : 02-525-8258, °ûÈ£ºó ÁÖÀÓ, hobin@kobia.kr
½Ã°£ | Title | ¹ßÇ¥ÀÚ | ºñ°í |
12:50-13:00 | Opening | KoBIA | |
13:00-13:30 | Speech 1£ºAntibody discovery and engineering to enable and expedite innovation | George Wang (Wuxi biologics / Vice President) | |
13:30-14:00 | Speech 2£ºEffective Engineering of Bispecific/Multispecific Antibodies for Biotherapeutics Development | Jiangqing Xu (Wuxi Biologics / Head of Protein Design and Enginnering Center of Excellence) | |
14:00-14:30 | Speech 3£ºEnable ADC development with highly efficient in vitro & in vivo characterizations | Lei Wu (Wuxi Biologics / Leader of the in vivo pharmacology group) | |
14:30-14:40 | Ending | KoBIA |
|